Pila Pharma AB ("Pila Pharma" or "the Company") announced on August 18, 2026, that it has received regulatory approval to conduct PP-CT04, a two-part, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and efficacy of XEN-D0501 in people living with obesity over 12 weeks. The study comprises a total of 46 participants and applies an individual dose escalation up to a maximum of 16 mg twice daily. Part 1 constitutes an initial safety cohort of eight participants with more intensive monitoring, while Part 2 comprises the remaining 38 participants and may commence following a favorable recommendation regarding the safety observed in Part 1.
In summary, the approval represents an important step for Pila Pharma, as clinical development in obesity can now be initiated and upcoming value drivers become to a greater extent results-driven. The study addresses the central question of higher doses and a longer treatment duration, while the dose-finding component is expected to create the conditions for continued development across more indications than obesity.
Read Analyst Group’s comment here (SWE & ENG)
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Pila Pharma. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.